Advances in antiretroviral, immune-based, and gene therapy for HIV infection in mothers and infants: Implications for future use in developing countries

Annals of the New York Academy of Sciences

Volumn 918, Issue , 2000, Pages 27-35

  Rubinstein, Arye ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; ZIDOVUDINE;

CHILD HEALTH CARE; CONFERENCE PAPER; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG CHOICE; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INTERNATIONAL COOPERATION; MATERNAL CARE; NONHUMAN; PATHOGENESIS; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0033638991     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05470.x     Document Type: Conference Paper

References (40)

1. Reduction of maternal-infant transmission of HIV-1 with zidovudine treatment
2. Maternal and infant outcomes with highly active antiretroviral therapy during pregnancy
3. 23-Valent pneumococcal polysacharide vaccine in HIV-1 infected Ugandan adults: Double blind, randomized and placebo controlled trial
4. Defective humoral immunity in pediatric acquired immune deficiency syndrome
5. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage φX174 in asymptomatic HIV-1 infected adults
6. + T cell responses associated with control of viremia
7. + cells provides a mechanism for lifelong persistence of HIV-1, even in patients of effective combination therapy
8. Immunological and virological characterization of individuals with long term nonprogressive HIV infection in a hemophilia cohort
9. Preserving HIV-1 specific T cell help: Will it prevent progression?
10. In vivo migration of and antiviral activity of transferred HIV specific CTLs
11. + cell depletion in SIV infected macaques
12. Intermittent drug therapy increases the time to HIV rebound in humans and induces the control of SIV after treatment interruption in monkeys
13. Controlled trial of IL-2 infusion in patients infected with HIV-1
14. + T cells in HIV-1 infected patients receiving HAART
15. Effects of antiretroviral therapy on immune reconstitution
16. Pediatric antiretroviral therapy
17. HIV-1 specific CTL responses in the first year of life
18. The transmission of Cr-51 tagged maternal erythrocytes from mother to fetus
19. Transplacental transmission of natural killer-cell lymphoma
20. Maternal viral load, zidovudine treatment, and the risk of HIV-1 transmission from mother to infant
21. Mother to child transmission of HIV-1: Correlation with neutralizing antibodies against primary isolates
22. Vertical transmission of HIV is correlated with low affinity/avidity maternal antibodies to the gp120 principal neutralizing domain
23. + T-cell counts and T-cell function in long-term AIDS free infection
24. Maternofetal transmission of HIV-1: The role of antibodies to the V3 primary neutralizing domain
25. Vertical transmission of HIV-1
26. Neutralizing antibody and perinatal transmission of HIV-1
27. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infection of macaque monkeys
28. HIV-1 neutralizing antibodies: How full is the bottle?
29. HIV-1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
30. Passive immunization with a human monoclonal antibody protects hu-PBL mice against challenge by primary isolates of HIV-1
31. Transport of recombinant human CD4-immunoglobulin G across the human placenta: Pharmacokinetics and safety in six mother-infant pairs in AIDS Clinical Trial Group protocol 146
32. Fetal immunization of baboons induces a fetal-specific antibody responses
33. Fetal immunizations by a DNA vaccine delivered into the oral cavity
34. Transplacental immunization of the human fetus to tetanus by immunization of the mother
35. A randomized, placebo controlled study of the immunogenicity of the HIV rgp 160 vaccine in HIV infected subjects with ≥400/ml CD4 T lymphocytes
36. Randomized trial of MN rgp120 HIV-1 vaccine in symptomless HIV-1 infection
37. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immune deficiency
38. Therapeutic immunization with recombinant gp160 in HIV-1 infection: A randomized double-blind placebo-controlled trial
39. Immunological and virological evaluations of HAART compared to HAART plus an inactivated HIV immunogen
40. Immunological and virological evaluations of HAART compared to HAART plus an inactivated HIV immunogen